Skepticism is very warranted here. And as I mention in your sibling comment, “promotes cancer recurrence” was a poor choice of term. “Permits,” due to the time between doses, would have been more accurate.
There are a lot of fly-by-night stories like this for a variety of reasons, be it ongoing research, funding seeking, or otherwise. I do believe the Benzimidazole class of medication mentioned is worth taking a deeper look at however—it seems to be a common thread over many of these.
Sometimes the reason something hasn’t seen use is more than the question of whether it’s clinically viable or not.
There are a lot of fly-by-night stories like this for a variety of reasons, be it ongoing research, funding seeking, or otherwise. I do believe the Benzimidazole class of medication mentioned is worth taking a deeper look at however—it seems to be a common thread over many of these.
Sometimes the reason something hasn’t seen use is more than the question of whether it’s clinically viable or not.